**Table 4** Univariable and multivariable Cox proportional hazard regression analyses of overall survival

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| Factor | Univariable analysis |  |  | Multivariable analysis |  |
| HR (95%CI) | P | HR (95%CI) | P |
| Gender |  |  |  |  |  |
| Male | Reference |  |  |  |  |
| Female | 1.376 (0.766-2.472) | 0.286 |  |  |  |
| Age at diagnosis |  |  |  |  |  |
| < 30y | Reference |  |  |  |  |
| ≥ 30 y | 1.450(0.839-2.507) | 0.183 |  |  |  |
| Primary site |  |  |  |  |  |
| Extremity | Reference |  |  |  |  |
| Trunk | 1.105 (0.620-1.971) | 0.735 |  |  |  |
| Tumor origin |  |  |  |  |  |
| Skeletal | Reference |  |  |  |  |
| Extraskeletal | 0.660 (0.346-1.261) | 0.209 |  |  |  |
| Stage |  |  |  |  |  |
| Localized | Reference |  |  | Reference |  |
| Metastatic | 2.269 (1.294-3.976) | 0.004 |  | 2.488 (1.413-4.383) | 0.002 |
| Diameter of primary tumor |  |  |  |  |  |
| < 8 cm | Reference |  |  |  |  |
| ≥ 8cm | 0.765 (0.434-1.351) | 0.356 |  |  |  |
| Local therapy |  |  |  |  |  |
| Surgery | Reference |  |  |  |  |
| Radiotherapy | 1.327 (0.654-2.692) | 0.432 |  |  |  |
| Surgery + radiotherapy | 1.271 (0.679-2.379) | 0.453 |  |  |  |
| Time to local therapy | 0.901 (0.733-1.107) | 0.329 |  |  |  |
| Number of chemotherapy cycles |  |  |  |  |  |
| < 12 | Reference |  |  | Reference | 0.003 |
| ≥ 12 | 0.505 (0.291-0.874) | 0.015 |  | 0.424 (0.240-0.748) |  |
| Frequency of chemotherapy delays |  |  |  |  |  |
| ≥ 25% | Reference |  |  | Reference |  |
| < 25% | 0.537 (0.270-1.067) | 0.076 |  | 0.438 (0.217-0.887) | 0.022 |
| Administration of dexrazoxane |  |  |  |  |  |
| YES | Reference |  |  |  |  |
| NO | 0.938(0.540-1.628) | 0.820 |  |  |  |

*HR* hazard ratio, *CI* confidence interval